Home › Funds › Virtus Biotech ETF
Fund family: ETFis Series Trust I · Filed by ETFis Series Trust I (CIK 1559109) · SEC series S000047354
Ticker: BBP (C000148682)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 496 with, 5 against, 0 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.
No item-level comparison with other ETFis Series Trust I funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.
The same votes as “with management” above, by the sector of the company voted on. 94.0% of this fund’s 501 such votes could be given a sector; the other 30 (6.0%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 471 | 5 | 1.1% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 290 | 0 |
| Audit-related | 64 | 0 |
| Say-on-Pay | 61 | 0 |
| Compensation | 49 | 0 |
| Corporate Governance | 23 | 3 |
| Capital Structure | 15 | 0 |
| Extraordinary Transactions | 2 | 0 |
| Other Social Issues | 2 | 1 |
| Environment or Climate | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Moderna, Inc. | May 6, 2026 | $11M | 5 | 0 |
| Iovance Biotherapeutics, Inc. | June 10, 2026 | $6M | 12 | 0 |
| TG Therapeutics, Inc. | June 11, 2026 | $4M | 8 | 0 |
| Moderna, Inc. | November 12, 2025 | $3M | 2 | 0 |
| BeOne Medicines Ltd. | June 11, 2026 | $3M | 32 | 0 |
| Ligand Pharmaceuticals Incorporated | June 5, 2026 | $3M | 11 | 0 |
| Exelixis, Inc. | May 26, 2026 | $3M | 14 | 0 |
| Biogen Inc. | June 9, 2026 | $3M | 12 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
507 ballot items at 60 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Virtus Biotech ETF (BBP) voted at 60 shareholder meetings of 59 companies, on 507 ballot items in all. Where management made a recommendation, the fund followed it on 99.0% of the items and voted against it 5 times. Its most frequent area of disagreement was corporate governance (3 of its votes against management). It voted on 5 shareholder proposals.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.